Suzano S.A. research snapshot
SUZ AI stock analysis currently reads Suzano S.A. as a low-cost global eucalyptus pulp leader with a real forest and mill advantage, but also a commodity business carrying substantial debt. At the August 3, 2026 research cutoff, the latest verified NYSE close used here was $8.52 on July 31, with a market capitalization near $10.5 billion. The stock traded above its 50-day moving average after a July rebound but remained below its 200-day moving average, and the next earnings report is scheduled for August 12, 2026. The central question is whether pulp prices, volume growth from the Ribas mill, tissue integration through the Arbex joint venture, cost discipline, and debt reduction can outweigh cyclical pricing, foreign exchange, and leverage risk. This is informational research only and is not investment advice.
Current price
$8.52 close on July 31, 2026
Market cap
About $10.5 billion
AI score
62 / 100
Rating
Cyclical value candidate with meaningful leverage
Trend status
Above the 50-day average, below the 200-day average, improving short-term momentum
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Suzano combines planted forests, mills, logistics, pulp, paper, tissue, and energy assets. Its core business is efficient, but realized prices remain cyclical and the tissue joint venture adds integration complexity. | High |
| Moat | The strongest moat is an integrated eucalyptus system with scale, seven-year tree rotations, low wood cost, mill proximity, and global distribution. It is a cost moat more than a pricing moat. | High |
| Management | Beto Abreu leads the company after a long Walter Schalka tenure. The team closed the Arbex tissue joint venture with Kimberly-Clark on July 1, 2026, while the main test is disciplined deleveraging after major investment and acquisitions. | Medium-high |
| Financial trend | FY2025 revenue rose to R$50.1 billion and net income returned to R$13.4 billion, but gross margin fell to 32.4% from 42.2% in 2024. 1Q26 revenue and adjusted EBITDA were down year over year and the TTM gross margin was 31.4%. | High |
| Valuation | At $8.52, the verified TTM inputs imply about 4.84x earnings, 1.14x book value, 12.72x free cash flow, and a 7.9% free cash flow yield. The low multiple partly reflects debt and commodity-cycle uncertainty. | High for inputs |
| Technical trend | Price was above the 50-day moving average of $8.17 and below the 200-day moving average of $9.17, while RSI near 62 showed improving but not extreme momentum. | Medium-high |
| Risk level | Risk is high relative to a typical defensive equity because pulp prices, currency, interest expense, climate, trade policy, the added Arbex debt, and net leverage can all change cash generation. | High |
| AI confidence | The factual business map is well supported by company filings and two market-data sources. Forecast confidence is lower because pulp prices and foreign exchange are difficult to model. | High data confidence |
| Investment certainty | Medium-low certainty. A strong cost position does not remove cycle risk, debt risk, or the possibility that a low multiple is justified. | Medium-low |
SUZ AI stock forecast
The SUZ AI stock forecast is presented as a three-year scenario range, not a deterministic price promise. The financial rigor model used a $1.76 TTM EPS input, annual EPS growth assumptions of 8%, 3%, and -5%, and target multiples of 7x, 5x, and 3.5x. Those assumptions produced reference values near $15.50, $9.60, and $5.30 before widening them into practical ranges. At the current $8.52 price, the base reference implies only a modest positive return, so the outcome depends heavily on pulp prices and debt reduction. A higher pulp price, stable demand, lower cash cost, tissue integration gains, and falling net leverage would improve the setup. More supply, weaker demand, a stronger Brazilian real, or delayed debt reduction would weaken it.
$13 to $16
More likely if pulp price increases hold, Ribas volume lifts sales without a cost spike, the Arbex joint venture adds tissue earnings, cash generation accelerates, and net leverage moves below 3x while investors assign a mid-cycle multiple.
$8 to $11
More likely if pulp remains cyclical but operational efficiency protects cash flow, EPS grows at a low single-digit rate, and the market keeps valuing SUZ near 5x normalized earnings.
$4.50 to $6
More likely if pulp prices fall again, demand or China-related volumes weaken, the real appreciates against export economics, Arbex adds more debt than earnings, or leverage stays high through a down cycle.
SUZ AI technical analysis
SUZ AI technical analysis shows a mixed structure at the July 31, 2026 close. The stock was above its 50-day moving average after a July rebound but remained below the 200-day moving average, and it had declined 9.36% over the prior 52 weeks. The levels below are planning zones from recent price history and public technical statistics, not live signals. Confirm them on a current chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $8.52 | Latest full NYSE close used for this page, July 31, 2026. |
| Near support | $8.05 to $8.20 | The 50-day moving average was $8.17 and mid-July pullback lows clustered near $8.05 to $8.15. |
| Near resistance | $8.53 to $8.58 | July swing highs reached $8.53 on July 28 and $8.58 on July 31. |
| Major resistance | $9.17 to $9.35 | The 200-day moving average was $9.17 and the 2025 year-end close was near $9.34. |
| 50-day moving average | $8.17 | Price closed above this short and medium-term reference at the data cutoff. |
| 200-day moving average | $9.17 | Price remained below this long-term reference, so the primary trend was still not confirmed as bullish. |
| Momentum | RSI 61.78 | The RSI reading was neutral to modestly bullish, above the 50 level. |
| Volume | 2.44 million average shares | Twenty-day average volume was about 2.44 million shares; the July 31 session volume was about 2.45 million. |
| Volatility | -9.36% over 52 weeks; beta 0.10 | The low beta does not remove commodity, currency, or gap risk around earnings and pulp-price updates. |
| Invalidation | Sustained close below $8.17 | A close back below the 50-day moving average would weaken the short-term recovery. A move above $8.58 and then $9.17 would improve the trend picture. |
SUZ AI trading strategy
The SUZ AI trading strategy is a rules-based framework, not personalized advice. It combines a commodity-cycle thesis with price confirmation, predefined risk, and monitoring of the data that can change the thesis.
Wait for price to break the $8.53 to $8.58 zone on stronger volume and then hold above the $9.17 200-day average. A sustained move above the 200-day average would provide stronger confirmation than a single-day spike.
A failed breakout or close back below the $8.17 50-day average reduces confidence. Do not treat a moving-average crossover as proof that pulp fundamentals have improved.
A range-based setup can watch the $7.56 to $7.80 support zone only if pulp prices stabilize, cash costs remain controlled, and net leverage is not rising.
A close below the 52-week low of $7.56 invalidates the range idea. Position size should reflect the possibility of a commodity drawdown, currency move, and the added Arbex leverage.
Track market pulp price, sales volumes, cash cost per tonne, operating cash generation, capex, net debt, debt maturity profile, FX hedges, the Arbex joint venture integration, and the 2Q26 results due August 12, 2026.
Lower confidence if adjusted EBITDA falls while debt stays above 3x, or if the tissue joint venture consumes cash without reducing group leverage.
Investment research summary
Suzano grows eucalyptus, converts wood into pulp and paper, and sells those fibers through a global production and logistics network. Customers pay for reliable fiber quality, scale, delivered cost, and supply continuity. Nearly all pulp production is integrated into its own paper needs or sold as market pulp, and a tissue and hygiene business now operates through the Arbex joint venture.
The moat is a cost system: favorable Brazilian growing conditions, genetic improvement, seven-year eucalyptus rotations, forests close to mills, integrated operations, port access, and 14.5 million tonnes of eucalyptus pulp capacity. Brand and switching costs matter more in tissue and specialty paper than in commodity pulp.
The thesis can fail through a prolonged pulp-price decline, oversupply, weak Chinese or global demand, a stronger Brazilian real, fires or drought, environmental conflict, higher interest costs, or acquisitions that consume cash without reducing leverage. The July 2026 Arbex closing added about USD 1 billion of joint venture net debt, so integration and deleveraging must deliver. The low multiple may be a warning about cycle and balance-sheet risk rather than a free bargain.
Beto Abreu became CEO on July 1, 2024 after leading Rumo and working across logistics, Shell, and Raizen. The team closed the USD 1.3 billion Arbex tissue joint venture with Kimberly-Clark on July 1, 2026, and the key capital-allocation test is converting scale into lower net debt. David Feffer remains chairman and held 4.2% of common shares as of March 23, 2026; the board, executive officers, and fiscal council together held 0.5%.
Paper is not a single secular growth market, but fiber demand remains tied to hygiene, packaging, tissue, and substitution of higher-cost long fibers. Eucalyptus and bio-based materials fit a longer shift toward renewable inputs, and tissue and hygiene provide a more stable demand base than commodity pulp. The 20-year question is whether Suzano compounds its cost and fiber advantages without letting capacity growth outrun demand.
The financial rigor check at $8.52 produced 4.84x TTM earnings, 1.14x book value, 12.72x free cash flow, a 7.9% FCF yield, and a 2.3% dividend yield from public TTM inputs. A margin of safety requires normalized cash flow and falling leverage, not only a low headline PE. The three-scenario model points to a wide $5.30 to $15.50 reference band before practical range adjustments.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SUZ price | $8.52 NYSE close on July 31, 2026 | StockAnalysis price history | August 3, 2026 |
| Market capitalization | About $10.5 billion; $8.52 x 1.24 billion shares = $10.56 billion, 0.33% from the reported $10.53 billion, consistent with the $10.57 billion at Macrotrends | StockAnalysis, Macrotrends, and financial_rigor.py | August 3, 2026 |
| Shares outstanding | 1.264 billion common shares at December 31, 2025 and March 23, 2026; 1.24 billion TTM basic shares in market data | Suzano 2025 Form 20-F and StockAnalysis | August 3, 2026 |
| FY2025 revenue | R$50.116 billion, up 5.72% year over year | Suzano 2025 Form 20-F and StockAnalysis | August 3, 2026 |
| FY2025 net income | R$13.408 billion, compared with a R$7.045 billion loss in 2024 | Suzano 2025 Form 20-F and StockAnalysis | August 3, 2026 |
| Five-year financial trend | Revenue R$40.965B, R$49.831B, R$39.756B, R$47.403B, R$50.116B from FY2021 to FY2025; FCF R$11.679B, R$6.892B, negative R$0.137B, R$4.233B, R$5.660B | StockAnalysis annual financial statements | August 3, 2026 |
| TTM operating data | Revenue R$49.531B, net income R$11.402B, FCF R$4.213B, and adjusted EBITDA R$21.451B | StockAnalysis and Suzano 1Q26 earnings release | August 3, 2026 |
| 1Q26 operating result | Revenue R$10.968B, adjusted EBITDA R$4.580B, operating cash generation R$2.521B, and net income R$4.312B | Suzano 1Q26 earnings release | August 3, 2026 |
| Debt and liquidity | 1Q26 gross debt R$90.736B, cash R$22.680B, net debt R$68.056B, and net debt to adjusted EBITDA of 3.2x in BRL or 3.3x in USD | Suzano 1Q26 earnings release | August 3, 2026 |
| Pulp scale and forest base | 14.5 million tonnes of eucalyptus pulp capacity, about 3.2 million hectares owned or leased, and about 1.7 million hectares of eucalyptus cultivation at December 31, 2025 | Suzano 2025 Form 20-F | August 3, 2026 |
| Arbex joint venture closing | On July 1, 2026, Suzano completed the USD 1.3 billion purchase of 51% of FamPro Tissue Holdings B.V. (Arbex) from Kimberly-Clark; the joint venture had about USD 1.0 billion of net debt | Suzano Form 6-K filed July 1, 2026 | August 3, 2026 |
| Technical statistics | 50-day moving average $8.17, 200-day moving average $9.17, RSI 61.78, average 20-day volume 2.44M, and beta 0.10 | StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Buy rating from 5 analysts with an average price target of $12.57, about 47.5% above the July 31, 2026 close; next earnings on August 12, 2026 | StockAnalysis forecast | August 3, 2026 |
| Scenario model inputs | TTM EPS $1.76, book value per share $7.45, FCF per share $0.67, dividend $0.19, and three-year reference values of $15.50, $9.60, and $5.30 | StockAnalysis and financial_rigor.py | August 3, 2026 |
This SUZ page is an information tool, not investment advice, a solicitation, or a guarantee of results. Forecasts are scenario ranges built from available data and assumptions that may be wrong. Market prices, financial statements, technical indicators, and company conditions can change after the stated cutoff.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
